PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8616978

Desogestrel.

S C Stone
View original source ↗Export metadata ↓

Abstract

Desogestrel is a new, potent progestogen with very low androgenic properties. When used as a contraceptive, it is a strong antiovulatory compound, even at low doses. The clinical efficacy is as good as that of the old progestogens. It has a low incidence of side effects and complications, similar to other progestogens. It may have a role as an anti-androgen in women with hyperandrogenic symptoms in need of adequate oral contraception.

Explore related subjects

Clinical Trials as TopicContraceptives, Oral, SyntheticDesogestrelFemaleHumansProgesterone CongenersBiologyBlood Coagulation EffectsCarbohydrate Metabolic EffectsCardiovascular EffectsContraceptionContraceptive AgentsContraceptive Agents, FemaleContraceptive Agents, ProgestinContraceptive EffectivenessFamily PlanningHematological EffectsHemic SystemLipid Metabolic EffectsLipidsLiterature ReviewMetabolic EffectsPhysiologyJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S C Stone. 1995. Desogestrel.. https://doi.org/10.1097/00003081-199538040-00017

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Group sequential monitoring of years of life saved with paired censored survival data.

This research develops non-parametric methodology for sequential monitoring of paired time-to-event data when comparing years of life saved, or years where any unpleasant outcome is delayed, is of interest. The recommended family of test statistics uses integrated differences in survival estimates that are available during the study period, where adjustments are made for dependence in the survival and censoring outcomes under comparison. In the context of paired censored survival data, the joint asymptotic closed form distribution of these sequentially monitored test statistics is developed and shown to have a dependent increments structure. Simulations verifying nice operating characteristics of the proposed monitoring methods also reveal consequences of ignoring an underlying paired data structure in terms of size and power properties. A motivating example is also presented via the Early Treatment Diabetic Retinopathy Study, which did not have methods available for sequentially monitoring paired censored survival data at the time.

Clinical Trials as Topic↗